Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

BACKGROUND: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the “coronavirus disease 2019” (COVID-19). However, the role of such agents as prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gendelman, Omer, Amital, Howard, Bragazzi, Nicola Luigi, Watad, Abdulla, Chodick, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406/
https://www.ncbi.nlm.nih.gov/pubmed/32380315
http://dx.doi.org/10.1016/j.autrev.2020.102566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406/
https://www.ncbi.nlm.nih.gov/pubmed/32380315
http://dx.doi.org/10.1016/j.autrev.2020.102566

Ejemplares similares